JBIO Overview

Jade Biosciences, Inc. is a biotechnology company, which is focused on developing therapies for autoimmune diseases. The Company’s lead asset, JADE-001, is an investigational anti-A PRoliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of Immunoglobulin A (IgA) nephropathy (IgAN), an autoimmune condition in which the kidney is damaged by pathogenic IgA containing immune complexes, leading to proteinuria and kidney function decline, and potentially progressing to end-stage kidney disease requiring dialysis or transplantation. Designed to block the APRIL protein, JADE-001 targets an underlying cause of IgAN, offering the potential to reduce pathogenic IgA levels, decrease proteinuria, and preserve kidney function over the long term. The Company’s pipeline also includes two undisclosed antibody discovery programs: JADE-002 and JADE-003, which are in preclinical development.

Wall Street analysts forecast JBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JBIO is23.75 USD with a low forecast of 17.00 USD and a high forecast of 28.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Jade Biosciences Inc revenue for the last quarter amounts to -43.45M USD, increased 1182.70

Jade Biosciences Inc. EPS for the last quarter amounts to -24081000.00 USD, increased 911.38

Jade Biosciences Inc (JBIO) has 55 emplpoyees as of June 21 2026.

Today JBIO has the market capitalization of 1.02B USD.